| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.56 | 85.6% |
| Total Income | 1.56 | 85.6% |
| Expenditure | 7.58 | 82.0% |
| PBT | -7.74 | 76.1% |
| Net Profit | -7.74 | 76.1% |
| OPM | — | |
| NPM | — | |
| EPS | -0.07 | 88.7% |
Wellgistics Health Reports Q1 2026 Financials
20 May 2026 · 20 May, 2:47 am
Summary
Wellgistics Health, Inc. reported financial results for the first quarter ended March 31, 2026. The company's focus on expanding direct sales from its Wellgistics Pharmacy segment led to sequential quarter over quarter growth. The company expects revenue of $1.775 million for Q2 2026. The company recorded a net operating loss of $7.742 million in the quarter ended March 30, 2026, compared to a net operating loss of $32.430 million for the quarter ended March 31, 2025.
Key Highlights
- 1
Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026.
- 2
The company's Q1 2026 focus was on optimizing Wellgistics Pharmacy revenue growth and capabilities.
- 3
The Kare Pharmtech joint venture expands the company’s telepharmacy and direct-to-patient capabilities, providing immediate access to 200,000+ patient lives.
- 4
The company expects revenue of $1.775 million for Q2 2026.
- 5
The company recorded a net operating loss of $7.742 million in the quarter ended March 30, 2026, compared to a net operating loss of $32.430 million for the quarter ended March 31, 2025.
- 6
Net operating loss per share for the quarter ended March 31, 2026 was $0.07 on 104.6 million weighted average shares outstanding.
Management Comments
Prashant Patel
“The Company’s first quarter focus on expanding direct sales from its Wellgistics Pharmacy segment led to sequential quarter over quarter growth that is now beginning to reach critical mass in the second quarter,” said Prashant Patel, RPh, President & Interim-CEO Prashant Patel. “We believe the sequential growth in Wellgistics Pharmacy revenue, together with our Kare Pharmtech joint venture, provides a foundation for continued expansion of our direct-to-patient initiatives. As we work to onboard patient lives available through the joint venture and prepare for the targeted August 2026 launch of the Health Lives Here initiative with Tollo Health and NFL Alumni Health, we are also continuing to advance the integration of PharmacyChain™ functionality with our EinsteinRx™ pharmacy dispensing AI hub.As we onboard an increasing percentage of the 200,000+ patient lives through the joint venture, we are preparing to support a significant ramp up in prescription dispending through our direct-to-consumer initiatives with Tollo Health coming from that planned August 2026 launch through the partnership with NFL Alumni Health of the “Health Lives Here initiative” that was revealed at the 2026 NFL Draft in Pittsburgh.” Mr. Patel continued, “As we engage with stakeholders in the pharmaceutical distribution space, we believe the GLP-1 market remains in an early stage of development and that products such as the Forzet™ medical food product, which is intended to support the dietary management of muscle loss associated with weight-loss therapies may represent an important adjunct opportunity,” We intend to increasingly focus on the GLP-1 segment and consolidate the capabilities required to provide what we believe to be a seamless end-to-end user experience that will likely lead to strong customer satisfaction and retention” “We believe the cost reduction and operating discipline implemented by management have better aligned the Company’s expense structure with its near-term revenue opportunities,”noted Mr. Patel.
Informational and educational content only. Not investment advice.